Search research articles
Contact Us
Filters
Showing results (201-210 of 221) with videos related to
Page
of 23
Sort By:
Advances in Experimental Medicine and Biology
|
February 23, 1999
Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E. coli nitroreductase gene
P F Searle, S J Weedon, I A McNeish, et al.
Lancet (London, England)
|
June 6, 2002
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial
T S Maughan, R D James, D J Kerr, et al.
Nuclear Medicine Communications
|
December 1, 1987
Arteriovenous shunting of microspheres in patients with colorectal liver metastases: errors in assessment due to free pertechnetate, and the effect of angiotensin II
J A Goldberg, M S Bradnam, D J Kerr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer
C V Christodoulou, D R Ferry, D W Fyfe, et al.
International Journal of Cancer
|
June 8, 2000
Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase
S J Weedon, N K Green, I A McNeish, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 4, 2000
A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints
D R Ferry, M Deakin, J Baddeley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2001
Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954
G Chung-Faye, D Palmer, D Anderson, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
January 23, 1999
Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine
P J Julyan, L W Seymour, D R Ferry, et al.
British Journal of Cancer
|
August 11, 2012
The TERT variant rs2736100 is associated with colorectal cancer risk
B Kinnersley, G Migliorini, P Broderick, et al.
British Journal of Cancer
|
December 1, 1996
Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution
D J Kerr, A M Young, J P Neoptolemos, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 221) with videos related to
Sort By:
Page
of 23
Advances in Experimental Medicine and Biology
|
February 23, 1999
Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E. coli nitroreductase gene
P F Searle, S J Weedon, I A McNeish, et al.
Lancet (London, England)
|
June 6, 2002
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial
T S Maughan, R D James, D J Kerr, et al.
Nuclear Medicine Communications
|
December 1, 1987
Arteriovenous shunting of microspheres in patients with colorectal liver metastases: errors in assessment due to free pertechnetate, and the effect of angiotensin II
J A Goldberg, M S Bradnam, D J Kerr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer
C V Christodoulou, D R Ferry, D W Fyfe, et al.
International Journal of Cancer
|
June 8, 2000
Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase
S J Weedon, N K Green, I A McNeish, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 4, 2000
A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints
D R Ferry, M Deakin, J Baddeley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2001
Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954
G Chung-Faye, D Palmer, D Anderson, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
January 23, 1999
Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine
P J Julyan, L W Seymour, D R Ferry, et al.
British Journal of Cancer
|
August 11, 2012
The TERT variant rs2736100 is associated with colorectal cancer risk
B Kinnersley, G Migliorini, P Broderick, et al.
British Journal of Cancer
|
December 1, 1996
Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution
D J Kerr, A M Young, J P Neoptolemos, et al.
Page
of 23